Cambridge Healthtech Institute’s Ninth Annual
Difficult to Express Proteins
Harnessing Innovation to Improve Expression and Function
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 5-6, 2014 | Seaport World Trade Center | Boston, MA
Membrane proteins, ion channels, toxic or insoluble proteins, low abundance protein complexes, vaccines and other “finicky” proteins often are the best choices for therapeutics, yet their successful expression is a minefield of failures and challenges. New technologies and novel methods can solve these problems and convert a finicky protein to a tractable one. This conference will present innovative and imaginative methods to make those difficult to express proteins more “expressible” and functional.
Harnessing the Patient’s Immune System to Combat Cancer
Bahija Jallal, Ph.D., Executive Vice President, MedImmune
Building One of the World’s Top Biotechnology Companies from the Ground Up: The Story of Regeneron
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories; CSO, Regeneron Pharmaceuticals, Inc.
Construct and Expression Optimization of the G Protein-Coupled Neurotensin Receptor for Structure Determination
Reinhard Grisshammer, Ph.D., Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases
Cell Biological Underpinnings Behind Difficult-to-Express Human IgGs
Haruki Hasegawa, Ph.D., Principal Scientist, Therapeutic Discovery, Amgen, Inc.
Artificial Environments and Quality Modulation of Cell-Free Expressed GPCRs: Case Studies of the Human Endothelin and Gonadotropin Releasing Hormone Receptors
Erika Orbán, Ph.D., Postdoctoral Fellow, Institute of Biophysical Chemistry, Goethe University
TAPBOOST Technology: Novel Technology to Enhance the Production of Hard-to-Produce Therapeutic Recombinant Proteins
Akinori Hishiya, Ph.D., Director, Biology, Boston Strategics Corporation
Rapid Screening of Membrane Protein Expression in Transiently Transfected Insect Cells
Hao Chen, Ph.D., Senior Scientist, Protein Technologies, Amgen, Inc.
Cell-Free Systems: Functional Modules for Synthetic and Chemical Biology
Marlitt Stech, M. Sc., Cell-free Protein Synthesis, Fraunhofer IBMT-Potsdam
High-Yield Membrane Protein Expression from E. coli using an Engineered Outer Membrane Protein F Fusion.
Bryan Berger, Ph.D., Head, Berger Lab; Assistant Professor, Chemical Engineering, Lehigh University
Nanolipoprotein Particles (NLPs) for Supporting Solubilization and Characterization of Membrane Proteins
Matthew A. Coleman, Ph.D., Adjunct Professor, Radiation Oncology, University of California Davis School of Medicine
Primary Structure Inspections to Improve Initial Expressions
Brian Chiswell, Ph.D., Owner and Founder, Dimensions BioSciences
Total Protein Engineering Solution for GPCRs through Stabilization and Construct Optimization
Markus Koglin, Ph.D., Associate Director, Protein Engineering, Heptares Therapeutics
Recovering Costly Labeled GPCRs from Dilute Solutions
Alexei Yeliseev, Ph.D., Staff Scientist, LMBB, NIH-NIAAA
Expressing Challenging Targets for Drug Discovery
Rick Davies, Ph.D., Reagents and Assay Development, AstraZeneca, Inc. (Attendance Tentatively Approved)
Additional Sponsored Presentation